Alterations in mRNA profiles of trastuzumab-resistant Her-2-positive breast cancer

Breast cancer is one of the most common malignancies in women. Neoadjuvant trastuzumab therapy improves the prognosis of certain Her-2-positive breast cancer patients, however around two-thirds of patients with Her-2-positive breast cancer do not benefit from Her-2-targeted therapy. To investigate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Bin, Zhao, Yang, Sun, Yan, Niu, Haitao, Sheng, Long, Huang, Dongfang, Li, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059662/
https://www.ncbi.nlm.nih.gov/pubmed/29750305
http://dx.doi.org/10.3892/mmr.2018.8981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059662/
https://www.ncbi.nlm.nih.gov/pubmed/29750305
http://dx.doi.org/10.3892/mmr.2018.8981

Ejemplares similares